ArticleImmunity2018
Anti-apoptotic Protein BIRC5 Maintains Survival of HIV-1-Infected CD4
Open access · bronzeAbstract read
In one paragraph
Article in Immunity, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers.
0numbers the graph read from it
0cells of the map it votes in
94citing papers in PubMed
8.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
94 citing papers in PubMed, 137 citations in OpenAlex.
- Intact HIV-1 proviruses accumulate at distinct chromosomal positions during prolonged antiretroviral therapy.The Journal of clinical investigation · 2019Trial
- BCL-2 inhibition at antiretroviral therapy initiation reduces the intact SIV reservoir in macaques.Nature microbiology · 2026Article
- PD-1 regulates CD4Nature communications · 2026Article
- Genetic and transcriptomic signatures of host control in HIV-1 infection.Retrovirology · 2026Article
- Methaneseleninic acid, a circadian-modulating agent, reactivates latent HIV-1 infection without cellular activation or proliferation.Journal of virology · 2026Article
- CD8bioRxiv : the preprint server for biology · 2026Article
- Cytotoxic CD4 T Cells: Dual Agents in HIV-1 Pathogenesis and Persistence.Current HIV/AIDS reports · 2026Review
- Resist to persist: resistance of the HIV reservoir to immune-mediated clearance.Current opinion in HIV and AIDS · 2025Review
- Host-directed approaches in the pursuit of a cure for HIV.Antiviral research · 2025Review
- Efficient mRNA delivery to resting T cells to reverse HIV latency.Nature communications · 2025Article
- Targeting Ikaros and Aiolos with pomalidomide fails to reactivate or induce apoptosis of the latent HIV reservoir.Journal of virology · 2025Article
- Phenotyping Viral Reservoirs to Reveal HIV-1 Hiding Places.Current HIV/AIDS reports · 2025Review
- Novel Core Gene Signature Associated with Inflammation-to-Metaplasia Transition in Influenza A Virus-Infected Lungs.International journal of molecular sciences · 2024Article
- Article
- Isotretinoin promotes elimination of translation-competent HIV latent reservoirs in CD4T cells.PLoS pathogens · 2024Article
- Review
- Comprehensive genome assembly reveals genetic diversity and carcass consumption insights in critically endangered Asian king vultures.Scientific reports · 2024Article
- CD4+ T cells with latent HIV-1 have reduced proliferative responses to T cell receptor stimulation.The Journal of experimental medicine · 2024Article
- Autoimmunity-associated allele of tyrosine phosphatase gene PTPN22 enhances anti-viral immunity.PLoS pathogens · 2024Article
- Dynamic modulation of the non-canonical NF-κB signaling pathway for HIV shock and kill.Frontiers in cellular and infection microbiology · 2024Review
34 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
16 authors at 6 institutions in 1 country.
Hsiao-Hsuan KuoInfectious Disease Division, Brigham and Women's Hospital, Boston, MA 02115, USA; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Rushdy AhmadBroad Institute of MIT and Harvard, Cambridge, MA 02139, USA.
Guinevere Q LeeInfectious Disease Division, Brigham and Women's Hospital, Boston, MA 02115, USA; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Ce GaoRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Hsiao-Rong ChenRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Zhengyu OuyangRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Matthew J SzucsBroad Institute of MIT and Harvard, Cambridge, MA 02139, USA.
Dhohyung KimInfectious Disease Division, Brigham and Women's Hospital, Boston, MA 02115, USA; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Athe TsibrisInfectious Disease Division, Brigham and Women's Hospital, Boston, MA 02115, USA.
Tae-Wook ChunNational Institute of Allergies and Infectious Diseases, Bethesda, MD 20892, USA.
Emilie BattivelliBuck Institute for Research on Aging, Novato, CA 94945, USA.
Eric VerdinBuck Institute for Research on Aging, Novato, CA 94945, USA.
Eric S RosenbergInfectious Disease Division, Massachusetts General Hospital, Boston, MA 02114, USA.
Steven A CarrBroad Institute of MIT and Harvard, Cambridge, MA 02139, USA.
Xu G YuInfectious Disease Division, Brigham and Women's Hospital, Boston, MA 02115, USA; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Mathias LichterfeldInfectious Disease Division, Brigham and Women's Hospital, Boston, MA 02115, USA; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02139, USA. Electronic address: mlichterfeld@partners.org.
Brigham and Women's Hospital · USBroad Institute · USRagon Institute of MGH, MIT and Harvard · USBuck Institute for Research on Aging · USMassachusetts General Hospital · USNational Institute of Allergy and Infectious Diseases · US
Funding
The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ARTHUR Y KIM · 2004 to 2026
$94.4MA Pilot Clinical Trial for HIV-1 EradicationU01AI117841 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI KURITZKES, DANIEL R., LICHTERFELD, MATHIAS · 2015 to 2020
$10.7MEarly Infant TreatmentU01AI114235 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI KURITZKES, DANIEL R., LICHTERFELD, MATHIAS · 2014 to 2020
$5.1MImmunoregulatory Function of Myelomonocytic Receptors in HIV-1 InfectionR01AI078799 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI YU, XU · 2008 to 2017
$4.1MA systems biology approach to fingerprint HIV immune defense in Elite ControllersR01HL134539 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI YU, XU · 2016 to 2019
$3.3MProteomics and phosphoproteomics analysis in HIV-1 infectionR01AI130005 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI LICHTERFELD, MATHIAS · 2017 to 2021
$2.9MQuantification of the HIV-1 Reservoir by Immuno-PCRR01AI120008 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI HEREDIA, ALONSO, LICHTERFELD, MATHIAS · 2015 to 2019
$1.9MInhibitors of host kinases as molecular targets for immune defense against HIV-1R01AI098487 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LICHTERFELD, MATHIAS · 2012 to 2015
$1.7MTargeting HIV-1 persistence with Interferon-aR33AI116228 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI YU, XU · 2016 to 2018
$1.5MViral and Immune Determinants of HIV ReboundR56AI125109 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI LI, JONATHAN · 2016 to 2016
$897kImageStream X Analyzer 2011S10OD012027 · OD · MASSACHUSETTS GENERAL HOSPITAL · PI PREFFER, FREDERIC IRA · 2012 to 2012
$595kPrimeFlow RNA for detection of latently-infected CD4+ T cellsR21AI124776 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI ROMERIO, FABIO · 2016 to 2017
$483kNHLBI NIH HHS R01 HL134539NIAID NIH HHS P30 AI060354NIAID NIH HHS R01 AI078799NIAID NIH HHS R01 AI098487NIAID NIH HHS R01 AI120008NIAID NIH HHS R01 AI130005NIAID NIH HHS R21 AI106468NIAID NIH HHS R21 AI116228NIAID NIH HHS R21 AI124776NIAID NIH HHS R33 AI116228NIAID NIH HHS R56 AI125109NIAID NIH HHS U01 AI114235NIAID NIH HHS U01 AI117841NIH HHS S10 OD012027
Abstract
HIV-1 infection of CD4
Indexed as
AdultAgedApoptosisCD4-Positive T-LymphocytesCell SurvivalFemaleHIV-1HIV InfectionsHumansMaleMiddle AgedSurvivinVirus LatencyYoung AdultBIRC5 protein, humanSurvivinapoptosisBIRC5clonal proliferationHIV-1latencyOX40proteomicsSurvivinviral reservoirs
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.